




The relative strengths and weaknesses of Agile Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Agile Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 93% points. The greatest weakness of Agile Therapeutics INC is the variable Research and Development, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 312%, being 49% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	38,085
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,934
Liabilities, Non-Current	0
Other Assets	309
Other Compr. Net Income	0
Other Expenses	-3,785
Other Liabilities	0
Other Net Income	-1,031
Other Revenues	0
Property and Equipment	12,318
Research and Development	25,622
Selling, General and Administrative Expense	7,467

Output Variable	Value in 1000 USD
Assets	50,712
Liabilities	7,934
Expenses	29,304
Revenues	0
Stockholders Equity	42,778
Net Income	-30,335
Comprehensive Net Income	-30,335
BaseVar	44,490
ECR before Limited Liability	215%
Economic Capital Ratio	312%